×
Passage Bio Total Assets 2020-2025 | PASG
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Passage Bio total assets from 2020 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
View More
Passage Bio Total Assets 2020-2025 | PASG
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Passage Bio total assets from 2020 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$222.5B
Amgen (AMGN)
$159.7B
Gilead Sciences (GILD)
$139.4B
Vertex Pharmaceuticals (VRTX)
$121.3B
Bristol Myers Squibb (BMY)
$96.3B
GSK (GSK)
$78.4B
CSL (CSLLY)
$77.4B
Regeneron Pharmaceuticals (REGN)
$61.6B
Alnylam Pharmaceuticals (ALNY)
$41.2B
Argenex SE (ARGX)
$34.4B
BioNTech SE (BNTX)
$26.7B
Royalty Pharma (RPRX)
$20.4B
Biogen (BIIB)
$19.5B
Insmed (INSM)
$19.3B
Illumina (ILMN)
$15.6B
Genmab (GNMSF)
$14.2B
Genmab (GMAB)
$13.8B
Incyte (INCY)
$13.5B
Moderna (MRNA)
$12.7B
Exelixis (EXEL)
$12.4B
BioMarin Pharmaceutical (BMRN)
$11.2B
QIAGEN (QGEN)
$10.7B
Ascendis Pharma (ASND)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.4B
Bio-Techne Corp (TECH)
$8.2B
Roivant Sciences (ROIV)
$7.9B
Regencell Bioscience Holdings (RGC)
$7.3B